Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from products and merchandise and other revenue increased. Growth in sales of key products and new products, increased exports of Hemlibra and NEMLUVIO, and higher one-time payments and royalty income contributed to the increase.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥663,331 million (YoY +14.7%) |
| Operating profit | ¥319,623 million (YoY +16.9%) |
| Ordinary income | ¥329,220 million |
| Profit attributable to owners of the parent | ¥231,749 million (YoY +19.2%) |
| Net income per share | ¥140.82 |
| Equity ratio | End of the current fiscal period 82.8 / End of previous period 82.1 |
| Total assets | ¥2,449,914 million |
| Net assets | ¥2,027,663 million |
| Cash flows from operating activities | ¥249,102 million |
| Cash flows from investing activities | ¥-36,049 million |
| Cash flows from financing activities | ¥-250,874 million |
| Cash and cash equivalents at end of period | ¥390,439 million |
| Full-year earnings forecast | Net Sales ¥1,345,000 million (YoY +6.9%) / Operating profit ¥670,000 million (YoY +7.5%) / Ordinary income Not disclosed / Net income ¥485,000 million (YoY +7.5%) |
| Annual Dividend Forecast | ¥272 → ¥132（-51.5%） |
| Payout ratio | 44.7 |
| Regional sales | ¥2,379 hundred million (YoY +6.5%), ¥3,286 hundred million (YoY +14.1%) |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | Number of newly consolidated companies 0 / Number of companies excluded 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors, securities analysts and the media |
| Issued Shares at Period-End | 1,679,057,667 |
| Treasury Shares at Period-End | 33,754,703 |
| Factors Behind Changes in Business Performance | Revenue from products and merchandise and other revenue increased. Growth in sales of key products and new products, increased exports of Hemlibra and NEMLUVIO, and higher one-time payments and royalty income contributed to the increase. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from products and merchandise and other revenue increased. In Japan, sales of key products and new products grew, while overseas exports of Hemlibra and NEMLUVIO increased, along with one-time payments and royalty income.